中国实用外科杂志

中国实用外科杂志 ›› 2023, Vol. 43 ›› Issue (03): 310-314.DOI: 10.19538/j.cjps.issn1005-2208.2023.03.12

• 专家论坛 • 上一篇    下一篇

局部进展期肝门部胆管癌新辅助治疗研究进展

长    江，李相成   

  1. 南京医科大学第一附属医院（江苏省人民医院）肝胆中心，江苏南京210029
  • 出版日期:2023-03-01 发布日期:2023-03-22

  • Online:2023-03-01 Published:2023-03-22

摘要： 肝门部胆管癌是恶性程度较高的胆道肿瘤，由于其起病隐匿，使得很多病人在就诊时已处于局部进展期甚至晚期，丧失根治性手术机。近年来的一些研究结果显示，新辅助治疗可以提高这部分病人的手术R0切除率，改善远期预后。但大多数研究仍停留在回顾性、小规模的阶段，尚缺乏大规模、多中心的研究。后续需要更多更大规模的随机对照来进一步确定新辅助治疗的有效性及安全性。

关键词: 肝门部胆管癌, 局部进展期, 新辅助治疗, R0切除

Abstract: Advance in neoadjuvant therapy for locally advanced hilar cholangiocarcinoma        CHANG Jiang, LI Xiang-cheng.  Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University(Jiangsu Province Hospital),  Nanjing, 210029, China
Corresponding author:LI Xiang-cheng, E-mail:drlixc@163.com
Abstract    Hilar cholangiocarcinoma（HCCA）is one kind of malignant biliary tract cancer. Its anonymous onset makes many patients already in locally progressive or even advanced stages at the time of diagnosis, depriving them of radical surgical opportunities. Several studies in recent years have shown that neoadjuvant therapy can improve R0 resection rate and improve the long-term prognosis of this group of patients. However, most studies are still in the retrospective and small-scale stage, and there is still a lack of large-scale，multi-center studies. More and larger randomized controlled trials are needed to further confirm the effectiveness and safety of neoadjuvant therapy.

Key words: hilar cholangiocarcinoma, locally advanced, neoadjuvant therapy, R0 resection